Company Analysis
Sign in

Sunshine Biopharma Inc. (SBFM)

Nasdaq: SBFM · Pharmaceutical Preparations · Fort Lauderdale, FL · filing with the SEC since 2007
Full chart Alerts Compare
Grade4.7
◀ Past 3.6● Present 5.8▶ Future 4.2
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Sunshine Biopharma Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.7/10
◀ Past3.630% of the headline
● Present5.840% of the headline
▶ Future4.230% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.6/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.1/10

Has it survived what it has been through?

23 warning events since 2017; the latest 2026-03-31.

weight 33% of this tense · 11th percentile among 497 sector filers · read for itself

From the record

Sunshine Biopharma Inc.'s filings since 2017 show 23 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2024-06-07); an auditor change (8-K item 4.01, 3 times, the latest 2025-09-30); a late-report notice (Form NT 10-K or NT 10-Q, 16 times, the latest 2026-03-31) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
7.0/10

What has it actually done, year after year?

9 filed years; profitable in 0 of 9.

weight 45% of this tense · 70th percentile among 323 sector filers · read for its customers

From the record

Sunshine Biopharma Inc.'s 9 filed years say what it did: it rose in 6 of 6 years; it never fell from a peak; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

  • the share of years revenue rosetop 8% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
0.5/10

How has it treated the people who own it?

SI estimate 0.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 5th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 5% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Sunshine Biopharma Inc.'s shareholder treatment is put at 0.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 5% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.8/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
5.4/10

Is it financially healthy right now?

ROE -26%: lost 26¢ per shareholder dollar. Leverage 23%: owes 23¢ per asset dollar.

weight 45% of this tense · 54th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Sunshine Biopharma Inc. lost about 26 cents for every dollar of shareholders' money, and gross profitability: its products earned about 41 cents per dollar of everything the company owns. Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count grew 492.4% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 37% of its family
  • return on equitytop 32% of its family
  • gross profit against assetstop 27% of its family
  • the share count against the year beforebottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
6.9/10

How strong is its position in its industry?

top 31% of 315 in its family; net margin -16.5%.

weight 33% of this tense · 69th percentile among 315 sector filers · read for its customers

From the record

Sunshine Biopharma Inc.'s standing among 315 graded names in its industry family: revenue of $36 million in fiscal 2025 ranks in the top 49% by size; a net margin of -16.5% ranks in the top 30%; revenue growth of 102.9% a year over the last 3 filed years ranks in the top 13% (its annual reports).

What it rests on

  • revenue against the family$36.3Mtop 49% of its family
  • net margin-16.5%top 30% of its family
  • three-year revenue growth102.9%top 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read
Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned
family median, 371 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Sunshine Biopharma Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.2/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
3.4/10

How much room does it have to grow?

bottom 34% of 273 in its family for room to expand.

weight 45% of this tense · 34th percentile among 273 sector filers · read for itself

From the record

Sunshine Biopharma Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $9 million against no long-term debt tagged leaves 30.3% of its assets as net cash, top 47% of its family; cash from operations less capital spending is -15.2% of revenue (top 36%); a gross margin of 33.8% (bottom 16%); research spending of 1.7% of revenue (bottom 3%) (its annual report).

What it rests on

  • cash less debt against assets30.3%top 47% of its family
  • cash from operations less capital spending against revenue-15.2%top 36% of its family
  • gross margin33.8%bottom 16% of its family
  • research spending against revenue1.7%bottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
4.5/10

What could actually drive growth from here?

bottom 45% of 306 in its family for growth drivers.

weight 33% of this tense · 45th percentile among 306 sector filers · read for its customers

From the record

Sunshine Biopharma Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 4.1% (bottom 44%); research spending grew -9.4% a year (bottom 32%); capital spending grew -3.5% a year (top 42%) (its annual reports). Sunshine Biopharma Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • the newest year's revenue growth4.1%bottom 44% of its family
  • three-year growth of research spending-9.4%bottom 32% of its family
  • three-year growth of capital spending-3.5%top 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
5.3/10

Did its newest year beat what its own record pointed to?

top 47% of 233 in its family for expectations against reality.

weight 22% of this tense · 53rd percentile among 233 sector filers · read for its shareholders

From the record

Sunshine Biopharma Inc.'s newest year against its own record: revenue of $36 million in fiscal 2025 came in 63.2% below the $99 million its prior three years' pace pointed to (bottom 15% of its family); net income of $6 million against a prior three-year average of $12 million (top 32%); a net margin of -16.5% against losses larger than its revenue before (top 26%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-63.2%bottom 15% of its family
  • net income against the prior three years' average+51%top 32% of its family
  • net margin against its prior averageup more than 100 pointstop 26% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SBFM · research, not advice